Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.

Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.

Human dihydroorotate dehydrogenase (hDHODH) is a class-2 dihydroorotate dehydrogenase. As a result of it’s extensively utilized by proliferating cells, its inhibition in autoimmune and inflammatory illnesses, cancers, and a number of sclerosis is of considerable scientific significance. On this examine, we had two goals. The primary was to develop an hDHODH pharma-similarity index strategy (PhSIA) utilizing built-in molecular dynamics calculations, pharmacophore speculation, and comparative molecular similarity index evaluation (CoMSIA) contour data methods. The strategy, for the invention and design of novel inhibitors, was primarily based on 25 numerous identified hDHODH inhibitors.

Three statistical strategies had been used to confirm the efficiency of hDHODH PhSIA. Fischer’s cross-validation check supplied a 98% confidence stage and the goodness of hit (GH) check rating was 0.61. The q(2), r(2), and predictive r(2) values had been 0.55, 0.97, and 0.92, respectively, for a partial least squares validation technique. In our strategy, every numerous inhibitor construction might simply be aligned with contour data, and customary substructures had been pointless. For our second goal, we used the proposed strategy to design 13 novel hDHODH inhibitors utilizing a scaffold-hopping technique. Chemical options of the strategy had been divided into two teams, and the Vitas-M Laboratory fragment was used to create de novo inhibitors. This strategy gives a useful gizmo for the invention and design of potential inhibitors of hDHODH, and doesn’t require docking evaluation; thus, our technique can help medicinal chemists of their efforts to determine novel inhibitors.

Meals-pharma convergence in medical nutrition- better of each worlds?

At current, industries throughout the well being and life science sector are shifting in direction of each other leading to new industries such because the medical vitamin business. Medical vitamin merchandise are particular dietary compositions for intervention in illness development and symptom alleviation. Trade convergence, described because the blurring of boundaries between industries, performs an important position within the shaping of recent markets and industries. Assuming that the medical vitamin business has emerged from the convergence between the meals and pharma industries, it’s essential to analysis how and which distinct business domains have contributed to determine this comparatively new business.

The primary two phases of business convergence (information diffusion and consolidation) are measured via patent evaluation. First, the extent of data diffusion throughout the medical vitamin business is graphed in a patent quotation interrelations community. Subsequently the consolidation primarily based on technological convergence is set via patent co-classification. Moreover, the medical vitamin core area and know-how interrelations are measured via a cross affect evaluation. This examine proves that the medical vitamin business is a results of meals and pharma convergence. It’s due to this fact essential for medical vitamin corporations to successfully monitor technological developments inside in addition to throughout business boundaries.

This examine additional reveals that though the medical vitamin business’s core know-how area is meals, technological improvement is principally pushed by pharmaceutical/pharmacological applied sciences Moreover, the outcomes point out that the business has surpassed the information diffusion stage of convergence, and is at present within the consolidation part of business convergence. Nonetheless, whereas the medical vitamin might be categorised as an business in a sophisticated part of convergence, one can not predict that the pharma and meals business segments will utterly converge or whether or not the medical business will change into a person profitable business.

Developments in scientific trials: a Pharma Issues report.

Because the pharmaceutical business strives to fulfill the ever-increasing complexity of drug improvement, new know-how in scientific trials has change into a beacon of hope. With large information comes the promise of accelerated affected person recruitment, real-time monitoring of scientific trials, bioinformatics empowerment of faster part development, and the overwhelming advantages of precision medication for choose trials. Danger-based monitoring stands to learn as effectively.

With a strengthening give attention to centralized information by the FDA and business’s transformative initiative, TransCelerate, a brand new period in trial threat mitigation has begun. The standard technique of intensive on-site monitoring is changing into a factor of the previous as statistical, real-time evaluation of website and trial-wide information gives the means to watch with larger effectivity and effectiveness from afar. Nonetheless, with regards to large information, there are challenges that lie forward. Affected person privateness, industrial funding safety, know-how woes and information variability are all limitations to be met with appreciable thought.

Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.

On the Annual Assembly of the American Academy of Dermatology this yr, scientific trials on psoriasis, atopic dermatitis and different pores and skin illnesses had been mentioned intimately. This evaluate of scientific analysis stories on novel therapies for psoriasis and atopic dermatitis reveals the affect of those illnesses and the drug candidates which were profitable in part II and III research.

Ethyl acetate Reagent

EC4600 1L
EUR 94.8

USP Sol. Lead Acetate TS

USP3101 100ML
EUR 80.94

USP Sol. Lead Acetate TS

USP3105 500ML
EUR 134.52

EP Reagent 0.1M Lead Nitrate

3003100 1L
EUR 58.14

Volumetric Sol Lead (II) Acetate 0.05M

PBA20051 1L
EUR 212.04

Volumetric Sol Lead (II) Acetate 0.05M

PBA20055 5L
EUR 422.94

Volumetric Sol Lead (II) Acetate 0.5M

PBA2051 1L
EUR 212.04

Volumetric Sol Lead (II) Acetate 0.5M

PBA2055 5L
EUR 422.94

EP Reagent Lead Sol. 0.1% Pb

5001700 100ML
EUR 118.56

EP Reagent Zinc Acetate Sol.

1102301 1L
EUR 274.74

Lead Acetate Solution (CH COO) Pb 10%

PBA101 1L
EUR 100.32

EP Reagent Congo Red Paper

1022002 PK100
EUR 388.74

EP Reagent Mercuric Bromide Paper

1052101 PK50
EUR 243.96

Pharmacopoeia 1M Cupriethylenediamine

3008700 1L
EUR 288.42

EP Reagent Conc to make Lead Sol. 100ppm Pb

5001701C 100ML
EUR 116.28

EP Reagent Acetate Buffer Sol. pH 4.6

4001400 1L
EUR 173.28

Lead

AG010 1 mg
EUR 627.6

Lead (Pb)

AT010 1mg
EUR 1641.6

isa lead

ISA30 ea
EUR 150

lead electrode

ISE30B ea
EUR 392.4

Standard for Lead Ise 475ML 0.1M Lead Perchlorate

948206 EACH
EUR 192.66

Lead(II) iodide

20-abx186488
  • EUR 260.40
  • EUR 493.20
  • EUR 360.00
  • 100 g
  • 1 kg
  • 500 g

Lead (II) chloride

LB0560 250g
EUR 71.48

EP Reagent Biuret Reagent

1011601 1L
EUR 42.18

EP Reagent Iodoplatinate Reagent

1046300 200ML
EUR 360.24

EP Reagent Methoxyphenylacetic Reagent

1053601 100ML
EUR 354.54

EP Reagent Molybdovanadic Reagent

1056700 100ML
EUR 42.18

EP Reagent Phosphomolybdotungstic Reagent

1065000 100ML
EUR 161.88

Lead (II) carbonate basic

LB0559 250g
EUR 71.48

Lead(II) oxide, 99%

GX3757-500G 500 g
EUR 156

Lead Nitrate Stock Solution

PBNO31 1L
EUR 607.62

EP Reagent Sulfomolybdic Reagent R3

1086500 1L
EUR 287.28

Amyl acetate (isomers of pentyl acetate and 2-pentyl acetate)

S-255 1ML
EUR 42.18

Elcatonin Acetate

5-01088 4 x 1mg Ask for price

Octreotide Acetate

5-01651 4 x 5mg Ask for price

Enfuvirtide Acetate

2440-1
EUR 183.6

Caspofungin acetate

2584-25
EUR 483.6

Caspofungin acetate

2584-5
EUR 170.4

Alarelin Acetate

A3151-100 100 mg
EUR 286.8
Description: Alarelin (Gonadotrophin-releasing hormone) is a synthetic GnRH agonist. Alarelin is found in higher amounts than that of LH-RH in rat hypophyseal stimulation of gonadotropin secretion in vivo and in vitro and in ovulation inductions.

Alarelin Acetate

A3151-1000 1 g
EUR 846
Description: Alarelin (Gonadotrophin-releasing hormone) is a synthetic GnRH agonist. Alarelin is found in higher amounts than that of LH-RH in rat hypophyseal stimulation of gonadotropin secretion in vivo and in vitro and in ovulation inductions.

Alarelin Acetate

A3151-50 50 mg
EUR 250.8
Description: Alarelin (Gonadotrophin-releasing hormone) is a synthetic GnRH agonist. Alarelin is found in higher amounts than that of LH-RH in rat hypophyseal stimulation of gonadotropin secretion in vivo and in vitro and in ovulation inductions.

Alarelin Acetate

A3151-500 500 mg
EUR 632.4
Description: Alarelin (Gonadotrophin-releasing hormone) is a synthetic GnRH agonist. Alarelin is found in higher amounts than that of LH-RH in rat hypophyseal stimulation of gonadotropin secretion in vivo and in vitro and in ovulation inductions.

Bazedoxifene acetate

A3233-10 10 mg
EUR 429.6
Description: Bazedoxifene, a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues.

Bazedoxifene acetate

A3233-25 25 mg
EUR 706.8
Description: Bazedoxifene, a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues.

Bazedoxifene acetate

A3233-5 5 mg
EUR 292.8
Description: Bazedoxifene, a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues.

Bazedoxifene acetate

A3233-50 50 mg
EUR 1112.4
Description: Bazedoxifene, a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues.

Desmopressin Acetate

A3360-10 10 mg
EUR 417.6
Description: Desmopressin acetate is the synthetic analogue of the antidiuretic hormone arginine vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.

Desmopressin Acetate

A3360-5 5 mg
EUR 297.6
Description: Desmopressin acetate is the synthetic analogue of the antidiuretic hormone arginine vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.

Desmopressin Acetate

A3360-5.1 10 mM (in 1mL DMSO)
EUR 505.2
Description: Desmopressin acetate is the synthetic analogue of the antidiuretic hormone arginine vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.

Desmopressin Acetate

A3360-50 50 mg
EUR 1470
Description: Desmopressin acetate is the synthetic analogue of the antidiuretic hormone arginine vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.

Flecainide acetate

A3418-10 10 mg
EUR 139.2
Description: Flecainide, a nonselective Na (+) channel blocker, is a class 1C antiarrhythmic drug, especially used for the management of supraventricular arrhythmia. Flecainide has been used extensively in the effect on providing long-term sinus rhythm (SR) restoration as well as decreasing AF symptoms.

Flecainide acetate

A3418-25 25 mg
EUR 247.2
Description: Flecainide, a nonselective Na (+) channel blocker, is a class 1C antiarrhythmic drug, especially used for the management of supraventricular arrhythmia. Flecainide has been used extensively in the effect on providing long-term sinus rhythm (SR) restoration as well as decreasing AF symptoms.

Flecainide acetate

A3418-50 50 mg
EUR 393.6
Description: Flecainide, a nonselective Na (+) channel blocker, is a class 1C antiarrhythmic drug, especially used for the management of supraventricular arrhythmia. Flecainide has been used extensively in the effect on providing long-term sinus rhythm (SR) restoration as well as decreasing AF symptoms.

Abiraterone acetate

A8202-5 5 mg
EUR 226.8
Description: Abiraterone acetate is the 3?-acetate form of its active component abiraterone, a potent inhibitor of androgen biosynthesis.

Abiraterone acetate

A8202-5.1 10 mM (in 1mL DMSO)
EUR 212.4
Description: Abiraterone acetate is the 3?-acetate form of its active component abiraterone, a potent inhibitor of androgen biosynthesis.

Abiraterone acetate

A8202-50 50 mg
EUR 714
Description: Abiraterone acetate is the 3?-acetate form of its active component abiraterone, a potent inhibitor of androgen biosynthesis.

Abiraterone acetate

A8202-S Evaluation Sample
EUR 97.2
Description: Abiraterone acetate is the 3?-acetate form of its active component abiraterone, a potent inhibitor of androgen biosynthesis.

Cyproterone Acetate

A8404-250 250 mg
EUR 142.8
Description: Cyproterone acetate has antagonistic properties towards the androgen receptor with an IC50 value of 7.1 nM. It can however, also act as a partial agonist of AR at an EC50 of 4.0 ?M.

Cyproterone Acetate

A8404-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Cyproterone acetate has antagonistic properties towards the androgen receptor with an IC50 value of 7.1 nM. It can however, also act as a partial agonist of AR at an EC50 of 4.0 ?M.

Leuprolide Acetate

A3551-10 10 mg
EUR 320.4
Description: Description:IC50 Value: N/ALeuprorelin (INN) or leuprolide acetate (USAN) is a GnRH analog. leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Leuprolide Acetate

A3551-25 25 mg
EUR 565.2
Description: Description:IC50 Value: N/ALeuprorelin (INN) or leuprolide acetate (USAN) is a GnRH analog. leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Leuprolide Acetate

A3551-5 5 mg
EUR 201.6
Description: Description:IC50 Value: N/ALeuprorelin (INN) or leuprolide acetate (USAN) is a GnRH analog. leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Leuprolide Acetate

A3551-50 50 mg
EUR 969.6
Description: Description:IC50 Value: N/ALeuprorelin (INN) or leuprolide acetate (USAN) is a GnRH analog. leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Antimony acetate

20-abx181235
  • EUR 226.80
  • EUR 309.60
  • 10 g
  • 50 g

Tetrabutylammonium acetate

20-abx181361
  • EUR 376.80
  • EUR 260.40
  • 100 g
  • 25 g

Eslicarbazepine acetate

abx184028-1g 1 g
EUR 927.6

Formamidine acetate

20-abx184088
  • EUR 744.00
  • EUR 510.00
  • 1 kg
  • 500 g

Guanabenz acetate

abx184101-50g 50 g
EUR 493.2

Prenyl acetate

20-abx184322
  • EUR 343.20
  • EUR 477.60
  • EUR 243.60
  • 100 g
  • 250 g
  • 25 g

Dehydroepiandrosterone Acetate

abx188674-200g 200g
EUR 627.6

Retinol Acetate

abx188867-5g 5 g
EUR 292.8

Chlormadinone acetate

B6136-100 100 mg
EUR 180
Description: Chlormadinone is a derivative of progesterone with antiandrogen and antigonadotropic effects.Progestogens can bind to nuclear receptor and then bind with DNA to form Progestogen Response Element, which will then activate the processes of transcription.

Chlormadinone acetate

B6136-5.1 10 mM (in 1mL DMSO)
EUR 201.6
Description: Chlormadinone is a derivative of progesterone with antiandrogen and antigonadotropic effects.Progestogens can bind to nuclear receptor and then bind with DNA to form Progestogen Response Element, which will then activate the processes of transcription.

Ulipristal acetate

B1049-5 5 mg
EUR 224.4
Description: Ulipristal acetate is a novel selective progesterone receptor modulator (SPRM) for the treatment of benign gynecological conditions such as uterine myoma.

Ulipristal acetate

B1049-5.1 10 mM (in 1mL DMSO)
EUR 393.6
Description: Ulipristal acetate is a novel selective progesterone receptor modulator (SPRM) for the treatment of benign gynecological conditions such as uterine myoma.

Ulipristal acetate

B1049-50 50 mg
EUR 1198.8
Description: Ulipristal acetate is a novel selective progesterone receptor modulator (SPRM) for the treatment of benign gynecological conditions such as uterine myoma.

Finasteride acetate

B1195-100 100 mg
EUR 166.8
Description: Finasteride acetate(MK-906,Proscar and Propecia) is a specific inhibitor of 5?-reductase and a drug of synthetic used in the benign prostatic hyperplasia (BPH) and the male pattern baldness (MPB) [1].

Finasteride acetate

B1195-200 200 mg
EUR 234
Description: Finasteride acetate(MK-906,Proscar and Propecia) is a specific inhibitor of 5?-reductase and a drug of synthetic used in the benign prostatic hyperplasia (BPH) and the male pattern baldness (MPB) [1].

Guanabenz Acetate

B1335-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Guanabenz Acetate is an selective agonist of ?2a-adrenergic receptor, ?2b-adrenergic receptor and ?2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.

Guanabenz Acetate

B1335-50 50 mg
EUR 122.4
Description: Guanabenz Acetate is an selective agonist of ?2a-adrenergic receptor, ?2b-adrenergic receptor and ?2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.

Guanabenz Acetate

B1335-S Evaluation Sample
EUR 97.2
Description: Guanabenz Acetate is an selective agonist of ?2a-adrenergic receptor, ?2b-adrenergic receptor and ?2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.

Megestrol Acetate

B1377-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Megestrol Acetate is a synthetic progesteronal and potent anti-estrogen agent with multiple drug actions [1].Megestrol Acetate has been reported to cause minor reduction of tumor size and prolonged survival time in Hepatocellular carcinoma (HCC).

Megestrol Acetate

B1377-50 50 mg
EUR 153.6
Description: Megestrol Acetate is a synthetic progesteronal and potent anti-estrogen agent with multiple drug actions [1].Megestrol Acetate has been reported to cause minor reduction of tumor size and prolonged survival time in Hepatocellular carcinoma (HCC).

Medroxyprogesterone acetate

B1510-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Medroxyprogesterone acetate(MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MP

Medroxyprogesterone acetate

B1510-50 50 mg
EUR 153.6
Description: Medroxyprogesterone acetate(MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MP

Medroxyprogesterone acetate

B1510-S Evaluation Sample
EUR 97.2
Description: Medroxyprogesterone acetate(MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MP

Sodium acetate

B7296-500000 500 g
EUR 134.4

Isopentyl acetate

B7890-100 100 mg
EUR 129.6

Isopentyl acetate

B7890-500 500 mg
EUR 199.2

Barium acetate

BB0116 250g
EUR 75.66

Butyl acetate

BC2500 1L
EUR 101.76

Lanreotide acetate

B2464-25
EUR 907.2

Lanreotide acetate

B2464-5
EUR 274.8

Octreotide acetate

B2582-25
EUR 496.8

Octreotide acetate

B2582-5
EUR 170.4

Semaglutide acetate

B3030-1 1 mg
EUR 163.2

Semaglutide acetate

B3030-5 5 mg
EUR 520.8

Mafenide Acetate

B3480-100 100 mg
EUR 200.4

Mafenide Acetate

B3480-1000 1 g
EUR 420

Mafenide Acetate

B3480-200 200 mg
EUR 240

Mafenide Acetate

B3480-5.1 10 mM (in 1mL DMSO)
EUR 180

Mafenide Acetate

B3480-50 50 mg
EUR 160.8

Mafenide Acetate

B3480-500 500 mg
EUR 320.4

Eslicarbazepine acetate

B3487-100 100 mg
EUR 373.2

Eslicarbazepine acetate

B3487-5.1 10 mM (in 1mL DMSO)
EUR 129.6

glatiramer acetate

B4978-25 25 mg
EUR 448.8
Description: Glatiramer acetate

glatiramer acetate

B4978-5 5 mg
EUR 184.8
Description: Glatiramer acetate

glatiramer acetate

B4978-5.1 10 mM (in 1mL DMSO)
EUR 309.6
Description: Glatiramer acetate

Octreotide acetate

B4979-10 10 mg
EUR 115.2
Description: Octreotide acetate (Sandostatin) is an octapeptide congener of native somatostatin, inhibits the secretion of insulin and glucagon. It reduces production of IGF-1 and IGF-2 by the liver by modulation of growth-hormone secretion from the pituitary gland.

Octreotide acetate

B4979-5.1 10 mM (in 1mL DMSO)
EUR 142.8
Description: Octreotide acetate (Sandostatin) is an octapeptide congener of native somatostatin, inhibits the secretion of insulin and glucagon. It reduces production of IGF-1 and IGF-2 by the liver by modulation of growth-hormone secretion from the pituitary gland.

Octreotide acetate

B4979-50 50 mg
EUR 157.2
Description: Octreotide acetate (Sandostatin) is an octapeptide congener of native somatostatin, inhibits the secretion of insulin and glucagon. It reduces production of IGF-1 and IGF-2 by the liver by modulation of growth-hormone secretion from the pituitary gland.

Ammonium acetate

AR0032 500g
EUR 74.62

Deoxycorticosterone acetate

B1724-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Deoxycorticosterone acetate is a steroid hormone used for intramuscular injection for replacement therapy of the adrenocortical steroid.

Deoxycorticosterone acetate

B1724-50 50 mg
EUR 153.6
Description: Deoxycorticosterone acetate is a steroid hormone used for intramuscular injection for replacement therapy of the adrenocortical steroid.

Fluorometholone Acetate

B1762-50 50 mg
EUR 235.2
Description: Fluorometholone Acetate is a synthetic corticosteroid, used in the treatment of steroid responsive inflammatory conditions of the eye.

Cortisone acetate

B1919-100 100 mg
EUR 142.8
Description: Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress.

Cortisone acetate

B1919-1000 1 g
EUR 268.8
Description: Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress.

Cortisone acetate

B1919-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress.

Cortisone acetate

B1919-500 500 mg
EUR 199.2
Description: Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress.

Dexamethasone acetate

B1926-100 100 mg
EUR 199.2
Description: Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant properties.

Dexamethasone acetate

B1926-5 5 mg
EUR 129.6
Description: Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant properties.

Dexamethasone acetate

B1926-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant properties.

Prednisolone Acetate

B2013-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Prednisolone Acetate

Prednisolone Acetate

B2013-50 50 mg
EUR 153.6
Description: Prednisolone Acetate

Prednisolone Acetate

B2013-S Evaluation Sample
EUR 97.2
Description: Prednisolone Acetate

Caspofungin Acetate

B2083-10 10 mg
EUR 170.4
Description: Caspofungin acetate(MK-0991), a new antifungal agent with minimal toxicity, inhibits synthesis of 1,3-?-D-glucan, an essential component of the fungal cell wall [1].

Information-focused highlights of novel dermatological trials, in addition to real-life large information approaches and an perception on the brand new methodology of risk-based monitoring, are all mentioned on this version of Developments in Scientific Trials.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>